XML 16 R7.htm IDEA: XBRL DOCUMENT
v3.25.1

Note 1 - Nature of the Business and the Basis of Preparation | 3 Months Ended
--- | ---
Mar. 31, 2025
Notes to Financial Statements |
Nature of Operations [Text Block] |
1. | Nature of the business and the basis of preparation
BeyondSpring Inc. (the “Company”) was incorporated in the Cayman Islands on November 21, 2014. The Company and its subsidiaries (collectively, the “Group”) are principally engaged in clinical stage biopharmaceutical activities focused on the development of innovative cancer therapies. The Company is under the control of Mr. Linqing Jia and Dr. Lan Huang as a couple (collectively, the “Founders”) since its incorporation. In January 2025, the Company entered into definitive agreements with three investors to sell a portion of Series A-1 Preferred Shares of SEED Therapeutics Inc. (“SEED”) owned by the Company, for gross proceeds of approximately $35,418. Upon completion of the transactions, the Company and SEED Technology Limited (“SEED Technology”), a majority-owned indirect subsidiary of the Company (collectively, the “BYSI Entities”) are expected to retain approximately 14.37% of SEED’s outstanding shares. See Note 3 – Discontinued operations for further information. As of March 31, 2025, the BYSI Entities owns approximately 40.12% of the outstanding equity interest in SEED, calculated on an as-converted basis. SEED continues to be consolidated into the financial statements of the Company since the Company remains substantive control of SEED. As of March 31, 2025, the subsidiaries of the Company are as follows:
Name of company | Place of incorporation | Date of incorporation |  | Percentage of ownership by the Group |  | Principal activities
BeyondSpring Pharmaceuticals Inc. (“BeyondSpring US”) | Delaware, U.S. | June 18, 2013 |  |  | 100% |  | Clinical trial activities
BeyondSpring Ltd. | The British Virgin Islands (“BVI”) | December 3, 2014 |  |  | 100% |  | Holding company
BeyondSpring (HK) Limited (“BeyondSpring HK”) | Hong Kong | January 13, 2015 |  |  | 100% |  | Holding company
Wanchun Biotechnology Limited (“BVI Biotech”) | BVI | April 1, 2015 |  |  | 100% |  | Holding company
Wanchun Biotechnology (Dalian) Ltd. (“Wanchun Dalian”) | People’s Republic of China (“PRC”) | April 23, 2015 |  |  | 100% |  | Holding company
Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”) | PRC | May 6, 2015 |  |  | 57.97% |  | Clinical trial activities
Beijing Wanchun Pharmaceutical Technology Ltd. (“Beijing Wanchun”) | PRC | May 21, 2018 |  |  | 57.97% |  | Holding company
SEED Therapeutics Inc. (“SEED”) | BVI | June 25, 2019 |  |  | 37.56% |  | Pre-clinical development activities
SEED Technology Limited (“SEED Technology”) | BVI | December 9, 2019 |  |  | 57.97% |  | Holding company
SEED Therapeutics US, Inc. (“SEED US”) | Delaware, U.S. | November 25, 2020 |  |  | 37.56% |  | Pre-clinical development activities
Wanchun Hongji (Dalian) Pharmaceuticals Ltd. (“Wanchun Hongji”) | PRC | March 22, 2022 |  |  | 37.56% |  | Pre-clinical development activities
The accompanying condensed consolidated balance sheet as of March 31, 2025, the condensed consolidated statements of comprehensive income (loss) for the three months ended March 31, 2024 and 2025, the condensed consolidated statements of shareholders’ deficit for the three months ended March 31, 2024 and 2025, the condensed consolidated statements of cash flows for the three months ended March 31, 2024 and 2025, and the related footnote disclosures are unaudited. These unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the U.S., or U.S. GAAP, for interim financial information using accounting policies that are consistent with those used in the preparation of the Company’s audited consolidated financial statements for the year ended December 31, 2024. Accordingly, these unaudited interim condensed consolidated financial statements do not include all of the information and footnotes required by U.S. GAAP for annual financial statements. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements contain all normal recurring adjustments necessary to present fairly the financial position, operating results and cash flows of the Group for each of the periods presented. The results of operations for the three months ended March 31, 2025 are not necessarily indicative of results to be expected for any other interim period or for the full year of 2025. The consolidated balance sheet as of December 31, 2024 was derived from the audited consolidated financial statements at that date but does not include all of the disclosures required by U.S. GAAP for annual financial statements. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2024.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 275 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 275 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 275 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details
Name: | us-gaap_NatureOfOperations
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration